Clinical Research Directory
Browse clinical research sites, groups, and studies.
Suvorexant and Alcohol
Sponsor: William Stoops
Summary
This research will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for alcohol, as well as other alcohol-associated maladaptive behaviors in people with Alcohol Use Disorder. This study will also provide basic science information about the orexinergic mechanisms underlying the pharmacodynamic effects of alcohol in humans. As such, the outcomes will contribute to our understanding of the clinical neurobiology of Alcohol Use Disorder. Overall, the proposed work seeks to expand the scope of current clinical neuroscience research on alcohol addiction by focusing on orexin, which has strong preclinical evidence supporting its critical role in addiction but remains unstudied in humans.
Official title: Influence of Orexin Antagonism on Motivation for Alcohol
Key Details
Gender
All
Age Range
21 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-06-07
Completion Date
2027-03-15
Last Updated
2025-12-23
Healthy Volunteers
Yes
Conditions
Interventions
Alcohol
The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.
Placebo
The effects of placebo will be determined.
Suvorexant
The effects of suvorexant dose 1 will be determined.
Suvorexant
The effects of suvorexant dose 2 will be determined.
Locations (1)
Psychopharmacology of Addiction Laboratory
Lexington, Kentucky, United States